COMPANY HISTORY

 In 2008, Dr. Tom Bayne and Kiran Krishnan realized the incredible potential of Bacillus spores  After 5 years, Kiran and his team of researchers achieved the very difficult task of stabilizing these spores for supplement manufacturing  In 2013, the company launched MegaSporeBiotic, its very first product, under the business name Physician’s Exclusive, LLC in Glenview, Illinois  Tom and Kiran attended 6 medical conferences, where they presented the compelling research they had discovered on the revolutionary probiotic.  In 2015 we initiated 2 of our first human clinical trials using a multi-spore product  In 2016, the company changed its name to Microbiome Labs  In 2017, the company moved its headquarters to St. Augustine, Florida, and attended over 85 conferences and seminars – In addition, we published our first human clinical trail on Megaspore and initiated 9 additional clinical trials.  This year, Microbiome Labs will be attending over 140 professional conferences and seminars as sponsors, invited speakers and educators. LEGACY PRODUCTS MEGASPOREBIOTIC

 100% spore-based probiotic containing Bacillus subtilis, B. coagulans, B. licheniformis, B. clausii, and B. indicus  4 Billion CFUs  NO refrigeration required  100% survival during digestion  Normal commensal gut flora  Controls bacterial overgrowths  Enhances growth of Lactobacillus, Bifidobacterium, Faecalibacterium, and more  Improves innate and adaptive immunity  Increases butyrate production by 40%  Enhances intestinal barrier function  Maintains efficacy during antibiotic therapy  Useful for: gut reconditioning, food sensitivities, allergies, inflammation

The effect of 30-days of probiotic supplementation on post-prandial responses to a high-fat meal: An Expanded Pilot Study Principal Investigator: Brian K. McFarlin, PhD, FACSM, FTOS University of North Texas

1.2

1.0

0.8

Over 60% 0.6 Difference between the groups

0.4 Change in Serum in Endotoxin Change

0.2

0.0 Baseline Post-Supplement Time The effect of 30-days of probiotic supplementation on post-prandial responses to a high-fat meal: An Expanded Pilot Study Principal Investigator: Brian K. McFarlin, PhD, FACSM, FTOS University of North Texas

180.0 SNEAK PREVIEW Spores 160.0

140.0

120.0

100.0

80.0 Megaspore Placebo 60.0

Change in Serum Triglycerides Serum in Change 40.0

20.0

0.0 Baseline Post-Supplement Time The effect of 30-days of probiotic supplementation on post-prandial responses to a high-fat meal: An Expanded Pilot Study Principal Investigator: Brian K. McFarlin, PhD, FACSM, FTOS University of North Texas

250.00 SNEAK PREVIEW

200.00

150.00

/mL)

pg 1 ( 1

- Megaspore

100.00 Placebo MCP

50.00

0.00 1-OH 1-3H 1-5H 2-0H 2-3H 2-5H Time The effect of 30-days of probiotic supplementation on post-prandial responses to a high-fat meal: An Expanded Pilot Study Principal Investigator: Brian K. McFarlin, PhD, FACSM, FTOS University of North Texas HU58

 High Potency Bacillus Subtilis HU58

 10 Billion CFUs

 NO refrigeration required

 100% survival during digestion

 Withstands extreme pH levels, high temperatures, dehydration, antibiotics, pressure, radiation, and even digestion  Produces over 12 targeted antibiotics of its own  Clinically shown to reduce blood ammonia levels  Useful for: gut reconditioning post-antibiotic treatments, SIBO, Candida overgrowths, UTIs, and hepatic encephalopathy

The effect of Probiotic Bacillus subtilis HU58 on Immune Function in Healthy Human Indian Practitioner Journal

PRE-PUBLICATION; HEPATIC ENCEPHALOPATHY RESTORFLORA

 Bacillus subtilis HU58, Bacillus clausii, and Saccharomyces boulardii  7 Billion CFUs  NO refrigeration required  100% survivability during digestion  Used in combination with MegaSporeBiotic  Useful for: acute and chronic diarrhea, gut reconditioning post- antibiotic treatments, SIBO, Candida overgrowths, and UTIs MEGAQUINONE

 Natural, soy-free source of vitamin K2 (MK-7)  Contains vitamin K1 and chelated cofactors to increase absorption  Removes calcium from tissues and arteries  Halts bone mineral density loss  Protects brain and nerve health from reactive oxygen species  Induces apoptosis in vitro with leukemia cells  Reduces risk of prostate and liver cancers  Improves insulin sensitivity after 4 weeks of supplementation  Enhances male fertility by increasing testosterone production MYOMAX

 Natural, soy-free source of vitamin K2 (MK-7)  330 mcg K2 + 200 mg calcium pyruvate for ATP production  Removes calcium from tissues and arteries  12% increase in maximal cardiac output  Improves mitochondrial efficiency  Protects brain and nerve health from reactive oxygen species  Induces apoptosis in vitro with leukemia cells  Reduces risk of prostate and liver cancers  Improves insulin sensitivity after 4 weeks of supplementation  Enhances male fertility by increasing testosterone production

25

CONCLUSION: Vitamin K2-7 supplementation was associated with a cardiovascular profile 20 characterized by increased cardiac output, Myomax-Base increased heart rate, and decreased blood lactate Myomax-Post compared to placebo following 8-weeks of exercise Placebo-Base training with the supplementation Placebo-Post 15 12% increase of Cardiac Output

Max Cardiac Output (L/min) CardiacOutput Max Equivalent to 60 liter more blood in 1 hour of work

“Without [vitamin K2-7] supplement, training induced 10 changes in maximal cardiac output could take 6 months of continuous training to achieve.” “Supplementation with [vitamin K2-7] during training appeared to reduce this training window by ~60%.” NEW PRODUCTS

Immunoglobulins Precision PrebioticTM Mucosal Support MEGA IGG2000

 Derived from bovine serum  Dairy-free – NO lactose, casein, or β-lactoglobulin  Stronger than colostrum powders

 Neutralize harmful pathogens like bacteria, viruses, and environmental toxins  Bind and eliminate unwanted toxins like lipopolysaccharide (LPS)  Reduce immune activation and inflammation  Strengthen immune tolerance

 45% IgG content vs 25% IgG content in colostrum MEGAPREBIOTIC

 Non-digestible food ingredient that feeds gut bacteria

Functional Fibers:  Xylooligosaccharides (XOS) from non-GMO corn  Fructooligosaccharides (FOS) from green and gold kiwi fruit  Galactooligosaccharides (GOS) from cow’s milk

 Selectively favors the growth of Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bifidobacteria species without feeding gut infections MEGAMUCOSA

Immunoglobulins  Bind and neutralize toxins

Amino acids  Increase mucin2 production  Rebuild mucosal barrier

Citrus polyphenols  Antioxidant properties  Increase short-chain fatty acid production  Reduce inflammation  Increase microbial diversity

DYSBIOSIS

LOW KEYSTONE STRAINS LOW DIVERSITY DISRUPTED MUCOSA DISRUPTED MUCOSA IMMUNE RESPONSE

DYSFUNCTIONAL GUT BARRIER

TOO MUCH LPS AND OTHER TOXINS “The disruption of gut microbiota has been implicated in many conditions and diseases, including obesity, inflammatory bowel disease, irritable bowel syndrome, type 2 diabetes, and colorectal cancer.”

“As we gain a deeper understanding of the specific relationships between the gut microbiota and disease, we expose potential therapeutic targets. Intelligent modulation of the intestinal community is a topic that had gained considerable interest and has the possibility to be extremely beneficial for human health.” “While some results related to dysbiosis in IBD are different between studies owing to variations of sample type, method of investigation, patient profiles, and medication, the most consistent observation in IBD is reduced bacterial diversity, a decrease of Firmicutes, and an increase of Proteobacteria.”

“A number of trials have shown that therapies correcting dysbiosis, including fecal microbiota transplantation and probiotics, are promising in IBD.” “A. muciniphila is inversely associated with obesity, diabetes, cardiometabolic diseases and low-grade inflammation.”

“Nowadays, A. muciniphila is widely considered as a novel potential candidate to improve metabolic disorders associated with obesity, diabetes, liver diseases and cardiometabolic disorders. Indeed, its administration has been shown to profoundly reduce the development of such diseases.” “The abundance of F. prausnitzii was decreased in IBD patients compared with healthy controls.”

“In summary, our meta-analysis and systematic review suggest a possible protective benefit of F. prausnitzii against the development of IBD. Therefore, further treatment such as probiotics or prebiotics to increase the levels of F. prausnitzii in IBD are lead to attempts.” “Three studies now characterize how gut epithelial barrier dysfunction is involved in IBD, autoimmune disease, and systemic infection.”

“Pathogenic bacteria can induce intestinal barrier defects and translocate to lymph nodes and liver, triggering systemic autoimmune disease, such as systemic lupus erythematosus (SLE).” “The results show that intestinal mucosal dysfunction characterized by an increased translocation of gram-negative bacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression.” “In the pathophysiology of GERD, abnormal exposure of the esophagus to luminal contents leads to chronic mucosal inflammation that is characterized by the release of IL-8 specifically, as well as other proinflammatory mediators, from the esophageal mucosa.”

“Hydrogen ions and gastric pepsin exert a corrosive effect on the surface of the esophageal mucosa and degrade junctional proteins, thereby destroying epithelial barrier function with the consequent induction of intramucosal inflammation.” “Early HIV infection is consistently associated with a rapid, dramatic, and largely irreversible depletion of mucosal CD4+ memory T-cells, particularly those expressing the HIV coreceptor CCR5.”

“In conclusion, further studies are needed to solve the complex riddle of how the interaction between primate lentiviruses and the host mucosal immune system leads to the severe mucosal immune dysfunction associated with progression to AIDS.”

RECONDITION REINFORCE the gut beneficial changes

REBUILD intestinal mucosa RECONDITION

• Many chronic diseases are associated with low microbial diversity in the gut • To revitalize a garden: remove the weeds, till the soil, and fertilize the plants • Bacillus spores do this by: • modulating the microbiota through quorum sensing • increasing short-chain fatty acid production by 40% • encouraging the growth of keystone bacteria like Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bifidobacteria

MegaSporeBiotic™ is the first 100% spore-based, broad-spectrum probiotic clinically shown to improve leaky gut by 60% in just 30 days. This unique all-spore formula effectively RECONDITIONS the gut by increasing microbial diversity and encouraging the growth of key health-promoting, commensal gut bacteria. REINFORCE

• The gut microbiome is a dynamic ecosystem that is constantly changing • Building a diverse, healthy garden requires the proper fertilizer • Most prebiotics can feed both harmful and beneficial bacteria • A Precision PrebioticTM can selectively feed important keystone strains, like Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bifidobacteria, which are associated with reduced risk of chronic disease

MegaPreBioticTM is the first Precision Prebiotic™ supplement made up of clinically-tested, non-digestible oligosaccharides that can increase microbial diversity and selectively feed beneficial bacteria. MegaPreBioticTM REINFORCES the beneficial microbial changes created by MegaSporeBioticTM to promote a strong and diverse microbiome. REBUILD

• A thick, gel-like mucus layer protects the intestinal lining from damage • Many chronic diseases are linked to the breakdown of the intestinal mucosa • Butyrate increases mucin production by up-regulating MUC2 genes • Bacillus spores and 4 amino acids can rebuild this intestinal barrier through the modulation of tight-junction proteins and butyrate-producing microbiota

MegaMucosaTM is the first complete mucosal support supplement of its kind, formulated with key amino acids to REBUILD a healthy mucosal barrier. MegaMucosaTM also contains dairy-free immunoglobulins clinically shown to support a healthy immune response in the mucosa and a state-of-the-art flavobiotic clinically shown to support microbial diversity and alleviate barrier dysfunction, otherwise known as leaky gut.

ONGOING RESEARCH . Prediabetes – Completed . Elevated Triglycerides – Completed . Rheumatoid Arthritis – Completed . Pre-Autoimmune Syndrome – Completed . Microbiota Modulation – Completed . Acne/Skin Microbiome . Weight Management . Gum Disease . C.dificil Control . Glyphosate on a child microbiome . 2nd Hepatic Encephalopathy study . 2nd Endotoxemia – Leaky gut study STUDIES ARE BEING CONDUCTED AT:

THANK YOU